Buy Rating Affirmed for Black Diamond Therapeutics Amid Promising NSCLC Treatment Advances
Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients With Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024
Daily futures tracking | Chip stocks have rebounded over the past few days, Nvidia and Broadcom single trading are active; gold and silver spot has soared, and related ETF bullish options have earned nearly 20 times overnight
Are bears sniping at Intel? The bearish ratio rose to 72%, and put trading volume increased dramatically; Broadcom rose by 3.97% to lead the rise in star technology stocks, and earned 6 times the profit from a single call due in October.
Stifel Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $15
Stifel analyst Bradley Canino maintains $Black Diamond Therapeutics(BDTX.US)$ with a buy rating, and maintains the target price at $15.According to TipRanks data, the analyst has a success rate of 41.
Wedbush Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $16
Wedbush analyst Robert Driscoll maintains $Black Diamond Therapeutics(BDTX.US)$ with a buy rating, and maintains the target price at $16.According to TipRanks data, the analyst has a success rate of 4
Piper Sandler Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $12
Piper Sandler analyst Joseph Catanzaro maintains $Black Diamond Therapeutics(BDTX.US)$ with a buy rating, and maintains the target price at $12.According to TipRanks data, the analyst has a success